Pharma Capital

NetScientific 'very pleased' to partner up with Merck for head and neck cancer trial

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI) tells Proactive their portfolio company PDS Biotechnology Corp and a subsidiary of Merck & Co Inc (NYSE: MRK), MSD are embarking on a new clinical trial collaboration for metastatic head and neck cancer.

 

View full NSCI profile

Netscientific PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.